Search Within

Nikita Navinchandra Mehta

Formats
  1. Journal Article (12)
  2. Correspondence (1)
  3. Editorial (1)
  4. Meeting Abstract (1)
  5. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (11)
  2. GSK Faculty (10)
  3. Human Oncology and Pathogenesis Program (10)
  4. Tow Center for Developmental Oncology (TCDO) (10)
  5. Center for Pancreatic Cancer Research (9)
  6. Clinical Genetics Service (9)

More Groups

People
  1. Diana Mandelker (10)
  2. Kenneth Offit (9)
  3. Zsofia Stadler (9)
  4. Alicia Latham (8)
  5. Maria Carlo (8)
  6. Michael Walsh (8)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (8)
  4. 2021 (2)
Publications
  1. Blood Advances (2)
  2. Genetics in Medicine (2)
  3. Blood (1)
  4. Cancer (1)
  5. European Urology (1)
  6. European Urology Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (3)
  2. American Society of Clinical Oncology (2)
  3. Nature Publishing Group (2)
  4. Wiley Blackwell (2)
  5. Biomed Central Ltd (1)
  6. Elsevier BV (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
    Journal Article

    Ceyhan-Birsoy, O.; Jayakumaran, G.; Kemel, Y.; Misyura, M.; Aypar, U.; Jairam, S.; Yang, C.; Li, Y.; Mehta, N.; Maio, A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias
    Journal Article

    Feurstein, S.; Hahn, C. N.; Mehta, N.; Godley, L. A.
    Genetics in Medicine (2022)

    Fulltext@MSK | Save
  • Evaluating the experiences of individuals with personal health risks identified through expanded carrier screening
    Journal Article

    Brown, E. M.; Grinzaid, K. A.; Ali, N.; Mehta, N.; Hardy, M. W.
    Journal of Genetic Counseling (2022)

    Fulltext@MSK | Save
  • Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation
    Journal Article

    Chui, M. H.; Yang, C.; Mehta, N.; Rai, V.; Zehir, A.; Momeni Boroujeni, A.; Ladanyi, M.; Mandelker, D.
    Journal of Pathology: Clinical Research (2022)

    Fulltext@MSK | Save
  • Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing
    Journal Article

    Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Paired tumor-normal sequencing provides insights into the TP53-related cancer spectrum in patients with Li-Fraumeni syndrome
    Journal Article

    Ceyhan-Birsoy, O.; Selenica, P.; Chui, M. H.; Jayakumaran, G.; Ptashkin, R.; Misyura, M.; Aypar, U.; Jairam, S.; Yang, C.; Li, Y.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save